Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | PDE5A | O76074 | 3/20 | 0.40 |
| ▸ | MPO | P05164 | 3/20 | 0.40 |
| ▸ | EGFR | P00533 | 6/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.38 |
| ▸ | ABL1 | P00519 | 2/20 | 0.38 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.38 |
| ▸ | SRC | P12931 | 2/20 | 0.38 |
| ▸ | KDR | P35968 | 2/20 | 0.38 |
| ▸ | AXL | P30530 | 1/20 | 0.38 |
| ▸ | PRKCI | P41743 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29576688 | 1.00 | LMNA (0.44) | LMNAHTTSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL29576662 | 0.89 | EGFR (0.46) | LMNASMN1; SMN2ALDH1A1MAPTEGFR | |
| SCHEMBL21176839 | 0.89 | EGFR (0.46) | LMNASMN1; SMN2ALDH1A1MAPTEGFR | |
| SCHEMBL15996428 | 0.85 | EGFR (0.49) | LMNAHTTMAPTEGFR | |
| SCHEMBL11769755 | 0.79 | PDE5A (0.40) | LMNAHTTSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL12978384 | 0.79 | ALDH1A1 (0.43) | LMNAHTTSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL11772709 | 0.79 | EGFR (0.45) | LMNAHTTSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL243787 | 0.79 | NR4A2 (0.47) | LMNAHTTSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL4989870 | 0.79 | CYP3A4 (0.41) | LMNAHTTSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL12201954 | 0.76 | KMT2A (0.37) | MAPTEGFRSRCAXLPRKCI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210177828-A1 | TAM FAMILY KINASE /AND CSF1R KINASE INHIBITOR AND USE THEREOF | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2021-06-17 | — | — | US | disclosed |
| US-20210177828-A1 | TAM FAMILY KINASE /AND CSF1R KINASE INHIBITOR AND USE THEREOF | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2021-06-17 | — | — | US | disclosed |
| EP-3741752-A1 | TAM FAMILY KINASE /AND CSF1R KINASE INHIBITOR AND USE THEREOF | Nanjing Transthera Biosciences Co., Ltd. (CN) | 2020-11-25 | — | — | EP | disclosed |
| EP-3741752-A1 | TAM FAMILY KINASE /AND CSF1R KINASE INHIBITOR AND USE THEREOF | Nanjing Transthera Biosciences Co., Ltd. (CN) | 2020-11-25 | — | — | EP | disclosed |
| WO-2019141202-A9 | TAM FAMILY KINASE /AND CSF1R KINASE INHIBITOR AND USE THEREOF | 南京药捷安康生物科技有限公司 | 2019-08-29 | — | — | WO | disclosed |
| WO-2019141202-A9 | TAM FAMILY KINASE /AND CSF1R KINASE INHIBITOR AND USE THEREOF | 南京药捷安康生物科技有限公司 | 2019-08-29 | — | — | WO | disclosed |
| WO-2019141202-A1 | TAM FAMILY KINASE /AND CSF1R KINASE INHIBITOR AND USE THEREOF | 南京药捷安康生物科技有限公司 | 2019-07-25 | — | — | WO | disclosed |
| WO-2019141202-A1 | TAM FAMILY KINASE /AND CSF1R KINASE INHIBITOR AND USE THEREOF | 南京药捷安康生物科技有限公司 | 2019-07-25 | — | — | WO | disclosed |
| US-8389721-B2 | Solubilized topoisomerase poisons | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2013-03-05 | — | — | US | disclosed |
| WO-2012015901-A1 | METHODS FOR TREATING GASTRIC AND PANCREATIC MALIGNANCIES | GENZYME CORPORATION (US) | 2012-02-02 | — | — | WO | disclosed |
| EP-1534681-A1 | SUBSTITUTED QUINOLINE CCR5 RECEPTOR ANTAGONISTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-06-01 | — | — | EP | disclosed |
| US-20050009825-A1 | Cytotoxic agents | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2005-01-13 | — | — | US | disclosed |
| US-20050009824-A1 | Solubilized topoisomerase poisons | RUTGERS, STATE UNIVERSITY OF NEW JERSEY, THE | 2005-01-13 | — | — | US | disclosed |
| EP-1465625-A2 | SOLUBILIZED TOPOISOMERASE POISONS | Rutgers, The State University (US) | 2004-10-13 | — | — | EP | disclosed |
| EP-1453812-A2 | CYTOTOXIC AGENTS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2004-09-08 | — | — | EP | disclosed |
| US-20040072818-A1 | Substituted quinoline CCR5 receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-04-15 | — | — | US | disclosed |
| WO-2004002960-A1 | SUBSTITUTED QUINOLINE CCR5 RECEPTOR ANTAGONISTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-01-08 | — | — | WO | disclosed |
| WO-2003041653-A2 | CYTOTOXIC AGENTS | RUTGERS, THE STATE UNIVERSITY (US) | 2003-05-22 | — | — | WO | disclosed |
| WO-2003041660-A2 | SOLUBILIZED TOPOISOMERASE POISONS | RUTGERS, THE STATE UNIVERSITY (US) | 2003-05-22 | — | — | WO | disclosed |
| US-3936461-A | Substituted 4-benzylquinolines | WARNER-LAMBERT COMPANY (US) | 1976-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009824-A1 | Solubilized topoisomerase poisons | TOP1, TOP2A, TOP2B | LMNA 128/4885HTT 4124/4885SMN1; SMN2 1565/4885 |
| US-20210177828-A1 | TAM FAMILY KINASE /AND CSF1R KINASE INHIBITOR AND USE THEREOF | CSF1R, CSF3R, FLT3 | LMNA 4729/4885HTT 4407/4885SMN1; SMN2 4693/4885 |
| US-20050009825-A1 | Cytotoxic agents | TOP1, TOP2A, TOP2B | LMNA 1151/4885HTT 1524/4885SMN1; SMN2 2104/4885 |
| US-20040072818-A1 | Substituted quinoline CCR5 receptor antagonists | CCR5, CXCR3, CCR2 | LMNA 4340/4885HTT 4237/4885SMN1; SMN2 4121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.